Literature DB >> 27882165

Emodin inhibits migration and invasion of MHCC-97H human hepatocellular carcinoma cells.

Wanfu Lin1, Maofeng Zhong1, Shufang Liang1, Yongan Chen1, Dong Liu1, Zifei Yin1, Qingxin Cao1, Chen Wang1, Changquan Ling1.   

Abstract

Emodin, an anthraquinone derivative from the root and rhizome of Rheum palmatum L., was found to have antitumor effects in different types of cancer by regulating multi-molecular targets. The aim of the present study was to explore the effect of emodin on the migration and invasion of MHCC-97H human hepatocellular carcinoma cells and the underlying molecular mechanisms. Firstly, it was demonstrated that emodin can inhibit cell proliferation and induce apoptosis of cells in a time- and dose-dependent manner, using a MTT assay and flow cytometry, respectively. However, when emodin concentration was <50 µmol/l, it had little effect on the inhibition of proliferation or the induction of apoptosis. Then, it was observed that emodin can significantly suppress cell migration and invasion with a treatment dose <50 µmol/l compared with the control (P<0.05), which was not attributed to a decrease in cell number. Further study demonstrated that emodin significantly suppressed the expression levels of matrix metalloproteinase (MMP)-2 and MMP-9 compared with the control, which may be mediated by the activation of the p38 mitogen-activated protein kinases (MAPK) signaling pathway and suppression of extracellular signal regulated kinase (ERK)/MAPK and phosphatidylinositol 3-kinase/Akt signaling pathways. Therefore, the present study, for the first time, used MHCC-97H cells, which have the high potential of malignant invasion, to demonstrate that emodin may inhibit cell migration and invasion.

Entities:  

Keywords:  emodin; human hepatocellular carcinoma; invasion; migration; molecular mechanisms

Year:  2016        PMID: 27882165      PMCID: PMC5103793          DOI: 10.3892/etm.2016.3793

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  33 in total

Review 1.  Current strategy for staging and treatment: the BCLC update and future prospects.

Authors:  Alejandro Forner; María E Reig; Carlos Rodriguez de Lope; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

2.  Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line.

Authors:  Zhen-Hua Sun; Ping Bu
Journal:  Exp Ther Med       Date:  2012-03-15       Impact factor: 2.447

Review 3.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

Review 4.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma.

Authors:  Mary Maluccio; Anne Covey
Journal:  CA Cancer J Clin       Date:  2012-10-15       Impact factor: 508.702

Review 5.  p38 MAP kinase: a convergence point in cancer therapy.

Authors:  James M Olson; Andrew R Hallahan
Journal:  Trends Mol Med       Date:  2004-03       Impact factor: 11.951

Review 6.  Role of p38 MAP Kinase Signal Transduction in Solid Tumors.

Authors:  Hari K Koul; Mantu Pal; Sweaty Koul
Journal:  Genes Cancer       Date:  2013-09

Review 7.  Role of traditional Chinese medicine and its chemical components in anti-tumor metastasis.

Authors:  Fengtan Li; Weisan Zhang
Journal:  J Cancer Res Ther       Date:  2014-08       Impact factor: 1.805

8.  Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.

Authors:  Aruljothi Subramaniam; Muthu K Shanmugam; Tina H Ong; Feng Li; Ekambaram Perumal; Luxi Chen; Shireen Vali; Taher Abbasi; Shweta Kapoor; Kwang Seok Ahn; Alan Prem Kumar; Kam M Hui; Gautam Sethi
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

Review 9.  Three advantages of using traditional Chinese medicine to prevent and treat tumor.

Authors:  Chang-quan Ling; Xiao-qiang Yue; Chen Ling
Journal:  J Integr Med       Date:  2014-07

10.  Sinulariolide Suppresses Human Hepatocellular Carcinoma Cell Migration and Invasion by Inhibiting Matrix Metalloproteinase-2/-9 through MAPKs and PI3K/Akt Signaling Pathways.

Authors:  Yu-Jen Wu; Choo-Aun Neoh; Chia-Yu Tsao; Jui-Hsin Su; Hsing-Hui Li
Journal:  Int J Mol Sci       Date:  2015-07-20       Impact factor: 5.923

View more
  5 in total

Review 1.  The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers.

Authors:  Qing Zhang; Wen Wen Chen; Xue Sun; Die Qian; Dan Dan Tang; Li Lin Zhang; Mei Yan Li; Lin Yu Wang; Chun-Jie Wu; Wei Peng
Journal:  Int J Biol Sci       Date:  2022-05-16       Impact factor: 10.750

Review 2.  Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin.

Authors:  Esra Küpeli Akkol; Iffet Irem Tatlı; Gökçe Şeker Karatoprak; Osman Tuncay Ağar; Çiğdem Yücel; Eduardo Sobarzo-Sánchez; Raffaele Capasso
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

3.  Oxymatrine inhibits the migration and invasion of hepatocellular carcinoma cells by reducing the activity of MMP-2/-9 via regulating p38 signaling pathway.

Authors:  Kunlun Chen; Pengfei Zhu; Jianwen Ye; Yuan Liao; Zhicheng Du; Fangfang Chen; He Juanjuan; Shaojin Zhang; Wenlong Zhai
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

4.  Effects of emodin, a plant-derived anthraquinone, on TGF-β1-induced cardiac fibroblast activation and function.

Authors:  Wayne Carver; Ethan Fix; Charity Fix; Daping Fan; Mrinmay Chakrabarti; Mohamad Azhar
Journal:  J Cell Physiol       Date:  2021-05-27       Impact factor: 6.513

5.  Wrist-ankle acupuncture attenuates cancer-induced bone pain by regulating descending pain-modulating system in a rat model.

Authors:  Chunpeng Zhang; Chen Xia; Xiaowen Zhang; Weimin Li; Xuerong Miao; Qinghui Zhou
Journal:  Chin Med       Date:  2020-02-04       Impact factor: 5.455

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.